Sight Sciences, Inc. logo

Sight Sciences, Inc.

SGHT

NASDAQHealthcareMedical - Devices

Latest quote

$8.24

+$0.11 · +1.35%

Aug 21, 3:55 PM ET

SGHT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

53

Fair Value

Momentum

42

Neutral

Sentiment

50

Mixed

Risk resilience

23

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Paul Badawi
Listed since
Jul 15, 2021
Employees
186

Market position

Volume
180.59K
0.72× average
Average volume
251.2K
Average daily volume
Market cap
449.43M USD
Beta
2.42
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
362.35M USD
P/E (TTM)
-14.79×
P/B (TTM)
8.51×
P/S (TTM)
5.39×
EV / EBITDA
-11.05×
Earnings yield
-9.29%
Free cash flow yield
-7.23%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
87.96%
Operating margin
-33.43%
Net margin
-35.69%
Return on equity
-60.10%
Return on assets
-33.33%
Return on invested capital
-35.42%

Financial health

Debt / equity
0.79×
Current ratio
10.22×

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+15.38%
11 comparable reports
Latest EPS result
-0.08
Estimate -0.18 · Beat by 56.36%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.07-0.16-0.24-0.33Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 5, 2025: actual -0.23, estimate -0.22, surprise -4.55%, Miss. Q2 2025, reported May 8, 2025: actual -0.28, estimate -0.29, surprise +3.45%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.23, estimate -0.25, surprise +8.00%, Beat. Q4 2025, reported Nov 6, 2025: actual -0.16, estimate -0.26, surprise +38.46%, Beat. Q1 2026, reported Mar 4, 2026: actual -0.08, estimate -0.15, surprise +46.67%, Beat. Q2 2026, reported May 6, 2026: actual -0.24, estimate -0.19, surprise -26.32%, Miss. Q3 2026, reported Aug 5, 2026: actual -0.08, estimate -0.183, surprise +56.36%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.13, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates24.49M21.85M19.21M16.57MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 5, 2025: actual 19.07M USD, estimate 18.5M USD, surprise +3.10%, Beat. Q2 2025, reported May 8, 2025: actual 17.51M USD, estimate 18.49M USD, surprise -5.31%, Miss. Q3 2025, reported Aug 7, 2025: actual 19.56M USD, estimate 17.74M USD, surprise +10.26%, Beat. Q4 2025, reported Nov 6, 2025: actual 19.91M USD, estimate 20.35M USD, surprise -2.20%, Miss. Q1 2026, reported Mar 4, 2026: actual 20.39M USD, estimate 20.35M USD, surprise +0.19%, Beat. Q2 2026, reported May 6, 2026: actual 19.7M USD, estimate 18.46M USD, surprise +6.68%, Beat. Q3 2026, reported Aug 5, 2026: actual 23.39M USD, estimate 21.72M USD, surprise +7.67%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 23.55M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$7.50

9.20% downside
Past 12 months12-month forecastHigh $8.00Average $7.50Low $7.00

Rating distribution

9 ratings
Strong buy00%
Buy444%
Hold444%
Sell111%
Strong sell00%

SGHT peers

ETFs holding SGHT

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research SGHT

research.disclaimer